UTSWRheum UTSWRheum
5 years 4 months ago
"Evidenced based medicine is not enough; you can perfectly execute the wrong decision." - Dr. Dino Kazi on the important role of clinical reasoning in patient care
#UTSWRheumGrandRounds
Dr. John Cush RheumNow
5 years 4 months ago
Great UTSW Rheum Grand Rounds by Dr. Dino Kazi on "Clinical Reasoning". Graphic shows stages of learning & Dunning Kruger effect describing gap of what we dont know but think we do know @UTSWRheum @UTSWIMchief @DinoKazi https://t.co/bFiWOJ2IXz
Dr. John Cush RheumNow
5 years 4 months ago
Checkpoint Inhibitor Safety in Melanoma Patients with AID
A study from the DMT shows that the use of checkpoint inhibitors for advanced melanoma in AID patients didn't increase the risk of irAEs, except for those with preexisting IBD.
https://t.co/VFzBOlc0wc https://t.co/0zfr8YFmZr
A French registry analysis compared the risk of diverticulitis and gastrointestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with biologics and found a greater risk of both in patients receiving tocilizumab (TCZ) compared with those on rituximab (RTX) or abatacept (ABA). It appears the increased risk with TCZ related to the increased risk of diverticulitis with TCZ.
The Journal of Bone & Joint Surgery reports the findings of a 4-year trial comparing outcomes of total ankle arthroplasty (TAA) versus ankle arthrodesis (AA) in patients with severe ankle arthritis; finding that while both groups improved, TAA was associated with less pain and better function after 4 years.
Dr. John Cush RheumNow
5 years 4 months ago
Good review of the epidemiology of Psoriatic disease - Psoriatic arthritis (PsA) is a chronic, progressive musculoskeletal disease that affects 0.1%–1% of the general population and ~20% of patients with psoriasis. Might wt loss be a prevention? https://t.co/kvoNqMMr7r
Dr. John Cush RheumNow
5 years 4 months ago
Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris. One year study of 135 moderate-to-severe pemphigus patients saw complete remission in 40% of RTX vs 10% of MMF patients. https://t.co/yAauFRjHCe
Dr. John Cush RheumNow
5 years 4 months ago
JAK inhibitor helping vitiligo? Results from phase 3 TRuE-V trial ruxolitinib cream in adolescent/adult vitiligo pts - showed significantly more RUX pts with 75% improvement in facial vitiligo area scoring index (F-VASI75) compared to control at Week 24 https://t.co/q98CBjfdQi
Dr. John Cush RheumNow
5 years 4 months ago
RNL 2021: Best of times, worst of times (Keynote): Dr. Iain McInnes
Dr. Iain McInnes presents his keynote lecture, Best of Times, Worst of Times..., at RheumNow Live 2021.
https://t.co/v3hOYuJZad
Dr. John Cush RheumNow
5 years 4 months ago
Rheumatologists--submit a question or case for Jack Cush and we may use it on an upcoming podcast.
https://t.co/wzNmOzH4VE https://t.co/pWbUcmLu2O
Dr. John Cush RheumNow
5 years 4 months ago
Dr. Jack Cush - Hemoptysis in Lupus
https://t.co/SjBazKiTW8
#LupusAwarenessMonth https://t.co/6z2R456Clm
Dr. John Cush RheumNow
5 years 4 months ago
Did you miss #RNL2021? We'll be sharing them on the site.
RNL 2021: Interstitial Lung Disease in RA - Dr. Jeff Sparks ( @jeffsparks )
https://t.co/0Z5PsWyMFH
Immune checkpoint inhibitors (ICI) are well known to cause immune-related adverse events (irAEs). A study from the Dutch Melanoma Treatment Registry shows that the use of checkpoint inhibitors for advanced melanoma in AID (autoimmune disease) patients did not increase the risk of irAEs, except for those with preexisting IBD.
Erosive hand osteoarthritis (EHOA) was studied as part of the Osteoarthritis Initiative, and shown to increase with advanced age and female sex, with developmental findings to suggest that EHOA as a disorder of skeletal frailty.
Dr. John Cush RheumNow
5 years 4 months ago
International survey by the World Lupus Federation of 6,100 lupus pts from over 85 countries shows 50% reporting decreased access to lupus healthcare; including /rheumatologist 36%, medical tests 29%, infusions 24%, meds 17% https://t.co/5tlbiP65gf
